JAK2 and myeloproliferative neoplasm: The JAK2 V617F mutation is associated with a group of hematopoietic malignancies termed myeloproliferative neoplasms (MPN), including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Vainchenker and Kralovics, 2017).